Gallery Jnj

25
Johnson+Johnso NYSE: JNJ Recommendation: Buy Connor Gallery “We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to reduce our costs in order to maintain reasonable prices.” - JNJ Credo November 18, 2008 “Caring for the world, one person at a time”

description

This presentation pitched Johnson & Johnson to my portfolio management class. The class voted to accept the stock into the class\'s $100,000 investment portfolio.

Transcript of Gallery Jnj

Page 1: Gallery Jnj

Johnson+Johnson

NYSE: JNJRecommendation: Buy

Connor Gallery

“We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to reduce our costs in order to maintain reasonable prices.”

- JNJ Credo

November 18, 2008

“Caring for the world, one person at a time”

Page 2: Gallery Jnj

Johnson+JohnsonIn 3 Sentences

• Johnson and Johnson is the world’s largest comprehensive and broadly based holding company and manufacturer of health care products.

• The company engages in the research, development, and sales of pharmaceuticals and diverse consumer staple products including Band-Aid, Tylenol, and Splenda.

• With sound financials, it competes in three major areas of health care including pharmaceutical products, medical devices and diagnostics, and consumer-health products.

Page 3: Gallery Jnj

Johnson+JohnsonKey Facts

• Founded 1885 in New Jersey• 250 companies in 57 countries• 119,200 employees• Market Cap: $165 Billion• Net Income: $12.6 Billion• $4.42 EPS Vs. Industry Average of $2.08• Profit Margin of 19.5% Vs. Industry Average of 10%• 52wk Range:52.06 - 72.7• Current Price: $59.29

Page 4: Gallery Jnj

Recent Acquisitions

Johnson+Johnson

Pfizer• 2005 Sales of Personal Care and OTC - $3.9b• Acquired many brands:

LISTERENE VISINESUDAFED NICORETTENEOSPORIN ZANTAC

• All Cash Transaction - $16.6b• Contributed 7.4 % to total growth rate in 2007

• Premier Consumer Health Care Company

• Combined make up 24.6% of Health Care Spyder

Page 5: Gallery Jnj

Market Strength

Johnson+Johnson

• Profitability• Low downside risk

• Extremely well diversified•Defensive in down market•Huge upside potential

• Broad product categories • Brand Recognition• Plays to its key strengths• 125 years of impressive history• R&D Budget - $7b• Master at acquisitions

Page 6: Gallery Jnj

Johnson+JohnsonIt Sells Itself

• The company has issued quarterly dividends to shareholders since 1944

• Sales have increased for 75 consecutive years

• One of four U.S. industrials with S&P and Moody’s triple A credit rating

Page 7: Gallery Jnj

Johnson+JohnsonGoodwill: 1982 Tylenol Murders

• Tylenol controlled approximately 37 percent of its market. Immediately after the cyanide poisonings, its market share was reduced to 7 percent (Mitchell 1989).

• Johnson and Johnson recalled all Tylenol in the United States

• To this day, Johnson and Johnson is studied in Harvard Case Studies for crisis management

Page 8: Gallery Jnj

Johnson+JohnsonConsumer Products

CLEAN & CLEAR AVEENO BAND-AID LISTERINEMOTRIN IB JOHNSONSNEUTROGENA PEPCID ACREMBRANDT SPLENDASUDAFED TYLENOL

Page 9: Gallery Jnj

Johnson+JohnsonPharmaceutical Focuses and Drug Therapies

Anti-infectiveAntipsychoticCardiovascularContraceptiveDermatologyGastrointestinalImmunologyNeurologyPain managementVirology

RisperdalInvegaProcitFloxinConcertaOrtho Evra

Page 10: Gallery Jnj

Johnson+JohnsonMedical Devices and Diagnostics

Circulatory disease managementOrthopedic joint reconstruction and spinal care

Wound care Women’s health

Minimally invasive surgicalBlood glucose monitoring and insulin delivery

Diagnostic productsDisposable contact lenses

Page 11: Gallery Jnj

Johnson+JohnsonWorld Health Care Spending

QuickTime™ and a decompressor

are needed to see this picture.

• World spending: $4 Trillion• JNJ Revenues: $53.3 Billion

• Piece of the action: 1.338 % Strategy = GROWTH!

Page 12: Gallery Jnj

Johnson+JohnsonAreas of Growth

• Sales in emerging markets expected to grow at 15% per year

• 250 operating companies• Consumer: McNeil• Medical: Ethicon• Pharma: Virco Lab

• Just acquired HealthMedia to move into wellness and health services

Page 13: Gallery Jnj

Johnson+JohnsonAreas of Growth: Consumer

• Who said a mature company can’t grow?

• Sales: $14.5b

• Growth rate: 48.3%

QuickTime™ and a decompressor

are needed to see this picture.

Page 14: Gallery Jnj

Johnson+JohnsonAreas of Growth: Pharmaceuticals

• Who said a mature company can’t grow?

• Sales: $24.9b

• Growth rate: 6.9%QuickTime™ and a

decompressorare needed to see this picture.

Page 15: Gallery Jnj

Johnson+JohnsonAreas of Growth: Medical

• Who said a mature company can’t grow?

• Sales: $21.7b

• Growth rate: 7.2%QuickTime™ and a

decompressorare needed to see this picture.

Page 16: Gallery Jnj

Johnson+Johnson

• The United States accounts for 53% of revenue• 2007 domestic revenue: $32.4 Billion

2007 Revenue Breakdown

QuickTime™ and a decompressor

are needed to see this picture.

QuickTime™ and a decompressor

are needed to see this picture.

Page 17: Gallery Jnj

Johnson+JohnsonGrowth Strategy

• Five-year compound annual growth:

• Worldwide - 11%• U.S. - 7.6%• International - 15.7%

• Issuing rebates to doctors

• Defend or renew patents

• Similar margins in all segments

Page 18: Gallery Jnj

Johnson+JohnsonThe Market - Qualitative Assessment

• The population is aging• Anti-aging cosmetics• Medical needs

• More countries can afford care

• The field is advancing rapidly

• Obama Administration

Page 19: Gallery Jnj

Johnson+Johnson

2001 Recession Performance

Page 20: Gallery Jnj

Johnson+Johnson

Current Market Position

Page 21: Gallery Jnj

Johnson+Johnson

Current Market Position: PharmaceuticalsCompetitors: Merck, Eli-Lilly, Bristol-Meyer, Schering - Plough

QuickTime™ and a decompressor

are needed to see this picture.

Page 22: Gallery Jnj

Johnson+Johnson

Current Market PositionPharmaceutical Index

QuickTime™ and a decompressor

are needed to see this picture.

Page 23: Gallery Jnj

Johnson+Johnson

Page 24: Gallery Jnj

Johnson+Johnson

Page 25: Gallery Jnj

Johnson+Johnson

Summary

• Largest Market Cap in Health Care • Invaluable Goodwill and Intangible Assets • Ability to weather bad times and capitalize in good times • Buy Johnson & Johnson